

As part of the Committee's oversight of the marketing practices of the pharmaceutical and device industry, Chairman Waxman sent letters (1) to Eli Lilly and AstraZeneca Pharmaceuticals requesting information related to Zyprexa (olanzapine) and Seroquel (quetiapine), drugs used to treat bipolar disease and schizophrenia; (2) to Boston Scientific Corporation and the Cordis Corporation requesting information on the companies' drug coated stents; and (3) to Cephalon regarding Actiq, a powerful narcotic lollipop, and Fentora, a narcotic lozenge, both approved to treat pain associated with cancer. **Documents and Links**

- [Letter to Cephalon on Actiq and Fentora](#)
- [Letter to Eli Lilly on Zyprexa](#)
- [Letter to AstraZeneca on Seroquel](#)
- [Letter to Boston Scientific on drug-eluting stents](#)
- [Letter to Cordis Corporation on drug-eluting stents](#)